<DOC>
	<DOC>NCT02804178</DOC>
	<brief_summary>This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of 5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.</brief_summary>
	<brief_title>A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Documented historical diagnosis of classic CAH due to 21OHD based on: Documented genetic mutation in the CYP21A2 enzyme consistent with a diagnosis of classic CAH, or historical documentation of elevated 17OHP Biochemical marker of disease status of 17OHP â‰¥ 4 X ULN Chronic glucocorticoid replacement therapy for at least 6 consecutive months Stable glucocorticoid and mineralocorticoid regimen for at least 1 month Nonclassic CAH Other causes of adrenal insufficiency Surgery within the previous 3 months prior to screening or planned surgery during study participation History of active cancer requiring medical or surgical therapy within the past 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ATR-101</keyword>
	<keyword>classic congenital adrenal hyperplasia</keyword>
	<keyword>21-hydroxylase deficiency</keyword>
	<keyword>CAH</keyword>
</DOC>